Cellectis (CLLS) – Globe Newswire
-
Cibus to Participate in the 36th Annual Roth Conference
-
European Parliament Votes to Support Proposal for the Regulation of New Genomic Techniques
-
Cibus Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call
-
Jim Collins to Join Cibus Board of Directors
-
Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
-
Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
-
Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annua
-
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
-
Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
-
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meet
-
Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
-
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
-
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
-
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
-
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
-
Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
-
Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
-
Cellectis Announces Pricing of Follow-On Offering
-
Cellectis Announces Launch of Follow-On Offering
-
Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
-
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
-
Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
-
Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
-
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
-
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
-
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
-
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
-
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
-
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
-
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
-
Cellectis to Report Third Quarter 2022 Financial Results
-
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
-
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
-
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
-
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
-
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
-
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
-
Cellectis to Report Second Quarter 2022 Financial Results
-
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
-
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
-
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
-
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
-
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
-
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
-
Cellectis to Report First Quarter 2022 Financial Results
-
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
-
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
-
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Back to CLLS Stock Lookup
